# Flomics Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/flomics-biotech

- Industry: Medical Devices & Equipment
- Headquarters: Barcelona, Spain
- Website: www.flomics.com
- Total disclosed funding: $1.2M
- Latest round: Seed (Mar 7, 2024)
- Investors on record: 3

## About

Founded in 2018 by Esther Lizano, João Curado, Luis Korrodi, and Nuno Alves, and based in Barcelona, Spain, Flomics Biotech operates as a biotech firm that develops blood-based diagnostic tools utilizing Next-Generation Sequencing (NGS) and advanced bioinformatics. In March 2024, Flomics Biotech raised EUR 1.1 million in seed funding led by an investor, with participation from Histemi Inversiones and Instituto Oncológico Dr. Rosell.

The firm develops technology that detects early-stage cancer through a multicancer blood test that identifies changes in RNA expression patterns before symptoms arise. The technology leverages liquid biopsies to analyze cell-free RNA in blood, providing insights into disease states across various organs from a single sample. Flomics combines RNA sequencing with machine learning to enhance diagnostic accuracy to detect disease-related RNA patterns efficiently.

The company intends to use the March 2024 funding to advance the development of its liquid biopsy technology and conduct preclinical validation for colorectal, lung, breast, prostate, and pancreatic cancers.

## Funding rounds

- Seed, Mar 7, 2024, $1.2M — Histemi Inversiones, Decelera Ventures, Instituto Oncológico Dr. Rosell

## Investors

- Histemi Inversiones — Seed
- Decelera Ventures (https://capitalatlas.ai/funds/decelera-ventures) — Seed
- Instituto Oncológico Dr. Rosell — Seed